18 February 2021
Visiongain has published a new report on Women’s Health Market Report 2021-2031: Forecasts by Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
GlobalWomen’s Health market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.
Women’s are on higher threat of getting infected with diseases such as osteoporosis, osteoarthritis, anaemia, menstrual health related disorders, depression and obesity. An upsurge in the population over 60 age, a rise in adoption of sedentary lifestyle habits, and the introduction of novel medicines for women are some of the factors that drive market growth.
COVID-19 Impact onWomen’s Health Market
In this period of COVID 19 pandemic, an awareness towards the health care is likely to increase among the people. Especially towards the women’s healthcare. Because women’s play an important role in an individual’s life. Moreover women’s have complicated issues regarding their health. Many programmes are running by various organisations regarding women’s care. In short COVID 19 pandemic is stimulating this market indirectly toward growth.
Changes in dietary habits, stress, and consumption of alcohol are the key factors responsible for hormonal imbalance among women. This is likely to cause fertility issues in women. Ovulation problems, endometriosis and polycystic ovarian syndrome are the major known factors for infertility. And these factors directs the Women’s Health Market towards growth.
The hormonal infertility sector is expected to grow rapidly owing to high fertility associated problems in developed countries. And the easy availability of several medicines to cure hormonal imbalance and market players’ investment in new product development would drive this segment towardsgrowth. Hormonal imbalance such as the imbalance of prolactin, estrogen,and thyroid is increasing in women due to factors such as stress,further driving the demand for medication to improve health. In turn this segment is proving as a substantial growth opportunity for the Women’s Health Market towards growth.
Some of the key players functioning in the market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer; Teva Pharmaceuticals; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb; and Ferring B.V. Partnerships for product development, enlargement of product portfolios, and geographical expansion in developing markets are the significant strategic endeavours of these companies to upsurge their market share.
Market player’s emphasis on gaining FDA approval for new disease symptoms to in order to prevent loss in revenues post-patent expiry. For instance, Prolia is suggested for postmenopausal women who are vulnerable to bone fractures due to osteoporosis. The symptoms differ according to the approvals across various geographies. In U.S. for instance, it is mainly used as a second or third level of treatment for women who have suffered at least one or multiple osteoporotic fractures. In Europe, it is recommended for women with a high threat of osteoporotic fractures and as a treatment of osteoporosis.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.
20 February 2024
The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.
19 February 2024
The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.
13 February 2024
The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.